Research from the COVID-19 Global Rheumatology Alliance included surveys and data gathering from rheumatology patients. During the pandemic era there was rapid adoption of telemedicine by rheumatologists; and a recent study of patient perspectives shows that most found telemedicine to be at least as effective as in-person clinic visits, especially in dealing with making medication changes and discussion of disease activity.
Most rheumatoid arthritis (RA) patients 65 and older who had 5 mg/day of prednisolone added to standard care were successfully weaned from the steroid without seeing substantial increases in disease activity, researchers said.
The American College of Rheumatology (ACR) said it has already joined with hundreds of organizations to submit 26 health policy comment letters to federal officials this year—surpassing the 24 letters the College submitted in 2022.
The Cleveland Clinic Journal has published a full-read review of postural orthostatic tachycardia syndrome (POTS), a condition often seen in clinic with symptoms like fibromyalgia, but is clinically diagnosed with finding sustained tachycardia upon standing without orthostatic hypotension.
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. This week highlights Veterans, Vegetarians and Antenatal Corticosteroids.
More often than not, conflict-of-interest disclosures in three major rheumatology journals didn't match records in the U.S. government's Open Payments database, researchers found.
A claims data study shows that maternal use of antenatal corticosteroids may be associated with an increased risk of serious infection in the offspring's first 12 months.
Johns Hopkins Hospital in Baltimore has been named the top hospital for rheumatology by U.S. News & World Report. This is the 6th year in a row they have held this spot.
The top 5 remain the same as last year with the only difference being the # 2 slot going to the Hospital for Special Surgery (HSS) in New York City. The other top centers include the Cleveland Clinic, Mayo Clinic and Brigham Hospital.
A novel B-cell depletion trial, using obexelimab (a bifunctional, monoclonal antibody that binds CD19 and Fc gamma receptor IIb), has shown efficacy and safety in patients with active IgG4-related disease.
An open-label, uncontrolled pilot trial has shown that JAK signaling is involved in the pathogenesis of PMR and that tofacitinib is as effective as glucocorticoids (GC) in patients with polymyalgia rheumatica (PMR).
Another study has confirmed that the intestinal microbiome's composition in people with inflammatory arthritis differs from that in other people, and in potentially unhealthy ways -- but whether the microbiome alterations actually cause arthritis is less clear. In fact, the investigators believe it's probably the other way around.
The Annals of Internal Medicine has published a predictive score to distinguish low-risk from high-risk inflammatory arthritis (IA) and who may benefit from risk stratification and preventive measures.
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week COVID persists, mortality from misdiagnosis, and cervical pain is more than a pain in the neck.
IL-23 inhibitors are approved for the treatment of psoriasis and psoriatic arthritis; a single center real-world observational study shows three commercially available IL-23 inhibitors have high and similar drug survival and effectiveness in difficult-to-treat psoriasis and PsA.
The prevalence of radiographic chondrocalcinosis is estimated to be 4% to ≥10% in older adults, but the prevalence of symptomatic calcium pyrophosphate deposition (CPPD) disease is unknown. To advance our understanding of CPPD, the American College of Rheumatology and EULAR have published validated classification criteria for symptomatic CPPD disease.
